Entourage Health Corp. (formerly WeedMD Inc.)
(
TSX-V:ENTG)
(OTCQX:ETRGF)
(FSE:4WE) (“
Entourage” or the
“
Company”), a Canadian producer and distributor of
award-winning cannabis products and brands, is pleased to announce
the Canadian launch of acclaimed Mary's Medicinals Transdermal
Patches (“Transdermal Patches”)*. Mary’s Medicinals is part of the
Mary’s Brands ("Mary's") portfolio and a BellRock Brands Inc.
company ("BellRock") (CSE: BRCK.U). As the exclusive manufacturer
and licensed distributor for Mary's suite of products in Canada,
Entourage launches Mary’s Transdermal Patches in CBD, THC and 1:1
formulations that will be available first to the Company’s Starseed
Medicinal patients as of late September 2021. Products are expected
to expand into the adult-use retail market later this year.
Mary’s Transdermal Patches – when applied as a
skin adhesive – could act as a novel and discreet delivery method
containing a THC, CBD and/or balanced 1:1 dosed formula and are
made with ingredients which are known to promote transdermal*
effects (absorption into body through the skin).
"With the launch of Mary’s Transdermal Patches,
we are taking a major step forward in offering our clients with
unique cannabis delivery methods for their self-care journey - and
more critically, could offer an alternative to debilitating opioid
use with a portfolio of safe and regulated cannabis delivery
systems," said Joseph Mele, Senior Vice President, Commercial,
Sales & Marketing. “Our roots in medical run deep and we are
fully committed to the continued expansion of our medical portfolio
that now includes over 40 SKUs of innovative products developed
alongside forward-thinking partners that allow us to cater to a
wider range of consumers seeking a discreet interface for cannabis
consumption."
Entourage is producing Mary’s Medicinals Canada
products in-house at its Aylmer, Ontario-based extraction hub,
using its own input biomass. The Company’s product development and
extraction teams are using Mary’s proprietary technology which
calls for extracting CBD, THC and CBN – the active cannabinoid
ingredients used to produce topical compounds and formulas for its
award-winning balms and patches.
With the expansion of Mary’s product suite, the
Company’s medical channel, Starseed continues to gather important
insights, data and client feedback. Starseed’s eligible patients
with benefits coverage may be able to purchase Mary’s products with
insured benefits.
Third-party* data suggest over 75% of Canadians
new to cannabis are interested in trying cannabis topicals and
transdermal methods as a relief for certain indications including
as an analgesic alternative (Reference: Nurturing New Growth;
Canada Gets Ready for Cannabis 2.0, Deloitte). A recent research
report from RBC Capital Markets forecasts the 2021 Canadian
concentrates-topicals sales market to be valued at approximately
C$227 million, as cannabis-curious Canadians look to try
non-intoxicating, next-generation cannabis products.
Starseed currently offers a comprehensive
medical marketplace and with the addition of the Transdermal
Patches, now has over 40 product SKUs available to its medical
clients. More recently, the Company introduced high-THC cultivars
Gelato33, Mandarin Cookies, and CannTx Life Sciences Inc.
(“CannTx”) cultivars Rockstar Tuna and Crown (Goddess). All are
specific, high-potency strains available to meet evolving patient
demand. Starseed also recently expanded its branded PAX® ERA® pods
to include house-cultivars Black Sugar Rose and Mango Haze.
CannTx Acquisition Business
Update
The Company also provided a business update on
the closing of the previously announced acquisition of CannTx by
Entourage (the “Acquisition”). Following
overwhelming approval from CannTx shareholders obtained in August
2021, upon satisfaction of all other customary and regulatory
consents, Entourage and CannTx expect to close the Acquisition
prior to the end of October 2021.
Visit Entourage Health’s newly launched website
here. To access our corporate video, visit us here and to access
our latest investor presentation and corporate deck here.
*This product contains ingredients that are
known to promote transdermal effects, however transdermal delivery
of cannabinoids by this product has not been tested.
About Entourage Health
Corp.
Entourage Health Corp. (formerly WeedMD Inc.) is
the publicly traded parent company of WeedMD RX Inc. a licence
holder producing and distributing cannabis products for both the
medical and adult-use markets. The Company owns and operates a
158-acre state-of-the-art greenhouse, outdoor and processing
facility located in Strathroy, ON as well as a fully-licensed
26,000 sq. ft. Aylmer, ON processing facility, specializing in
cannabis extraction. With the addition of Starseed Medicinal, a
medical-centric brand, Entourage has expanded its multi-channeled
distribution strategy. Starseed’s industry-first, exclusive
partnership with LiUNA, the largest construction union in Canada,
along with employers and union groups complements Entourage’s
direct sales to medical patients. In July 2021, Entourage signed a
definitive agreement to acquire craft cultivator CannTx Life
Sciences Inc. which operates out of its state-of-the-art
micropropagation and specialty extraction facility in Guelph,
Ontario. Upon the expected closing in October 2021, craft brand
Royal City Cannabis will be added to Entourage’s elite product
portfolio. The Company maintains strategic relationships in the
seniors’ market and supply agreements with Shoppers Drug Mart as
well as eight provincial distribution agencies where adult-use
brands Color Cannabis and Saturday Cannabis are sold. Entourage is
also the exclusive Canadian producer and distributor of
award-winning U.S.-based wellness brand Mary’s Medicinals sold in
both medical and adult-use channels.
For more information, please visit us at
www.entouragehealthcorp.com
Follow Entourage and its brands on
LinkedIn
Twitter: Entourage,
Color Cannabis, Saturday
Cannabis &
Starseed
Instagram:
Entourage, Color
Cannabis, Saturday
Cannabis &
Starseed
For further information, please
contact:
For Investor Enquiries:Valter
PintoManaging Director KCSA Strategic
Communications1-212-896-1254entourage@kcsa.com
For Media Enquiries:Marianella
delaBarreraSVP, Communications & Corporate
Affairs416-897-6644marianella@weedmd.com
Forward Looking Information
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon Entourage's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information in this press release
includes, but is not limited to, information in respect of the
manufacture and distribution of cannabis-infused beverages pursuant
to the development, supply, manufacturing, sales and marketing
agreements entered into by the Company and the prospects
thereof.
The forward-looking information in this news
release is based upon the expectations, estimates, projections,
assumptions and views of future events which management believes to
be reasonable in the circumstances. Forward-looking information
includes estimates, plans, expectations, opinions, forecasts,
projections, targets, guidance or other statements that are not
statements of fact. Forward-looking information necessarily involve
known and unknown risks, including, without limitation, risks
associated with general economic conditions; adverse industry
events; loss of markets; future legislative and regulatory
developments; inability to access sufficient capital from internal
and external sources, and/or inability to access sufficient capital
on favourable terms; the cannabis industry
in Canada generally; the ability of Entourage to
implement its business strategies; the COVID-19 pandemic;
competition; crop failure; and other risks.
Any forward-looking information speaks only as
of the date on which it is made, and, except as required by law,
Entourage does not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for Entourage to predict all
such factors. When considering this forward-looking information,
readers should keep in mind the risk factors and other cautionary
statements in Entourage’s disclosure documents filed with the
applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in the
disclosure documents could cause actual events or results to differ
materially from those described in any forward-looking
information.
Third Party Information This
press release includes market and industry data that has been
obtained from third party sources, including industry publications.
The Company believes that the industry data is accurate and that
its estimates and assumptions are reasonable, but there is no
assurance as to the accuracy or completeness of this data. Third
party sources generally state that the information contained
therein has been obtained from sources believed to be reliable, but
there is no assurance as to the accuracy or completeness of
included information. Although the data is believed to be reliable,
the Company has not independently verified any of the data from
third party sources referred to in this press release or
ascertained the underlying economic assumptions relied upon by such
sources.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE
Entourage Health (TSXV:ENTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Entourage Health (TSXV:ENTG)
Historical Stock Chart
From Jul 2023 to Jul 2024